Therapeutic targeting of tumor suppressor genes
Abstract
Carcinogenesis is a multistep process attributable to both gain‐of‐function mutations in oncogenes and loss‐of‐function mutations in tumor suppressor genes. Currently, most molecular targeted therapies are inhibitors of oncogenes, because inactivated tumor suppressor genes have proven harder to “drug.” Nevertheless, in cancers, tumor suppressor genes undergo alteration more frequently than do oncogenes. In recent years, several promising strategies directed at tumor suppressor genes, or the pathways controlled by these genes, have emerged. Here, we describe advances in a number of different methodologies aimed at therapeutically targeting tumors driven by inactivated tumor suppressor genes. Cancer 2015;121:1357–1368. © 2014 American Cancer Society.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 29, 2014
- Source ID
- 10.1002/cncr.29140
Entities
People
- Luc G T Morris
- Timothy A Chan
Organizations
- Adenoid Cystic Carcinoma Research Foundation
- Damon Runyon Cancer Research Foundation
- Memorial Sloan Kettering Cancer Center
- Sontag Foundation
- United States Department of Defense